Fly News Breaks for December 18, 2019
Dec 18, 2019 | 12:45 EDT
Nomura Instinet analyst Christopher Marai raised his price target for Solid Biosciences shares to $10 from $6 after the company announced three-month biopsy results from its microdystrophin program that has him encouraged that the bear case of an "ineffective drug" is now off the table. The risk/benefit profile of SGT-001 has improved and "likely portends a quick resolution to the current clinical hold," according to Marai, who keeps a Buy rating on Solid shares.
News For SLDB From the Last 2 Days
There are no results for your query SLDB